CHICAGO--(BUSINESS WIRE)--Genentech, Inc. (NYSE: DNA) today announced results from early studies of several investigational cancer agents targeting the HER (human epidermal growth factor receptor) pathway and pro-apoptotic receptors that induce apoptosis (cell death). These results, including data from studies of pertuzumab, trastuzumab-DM1 (T-DM1), Apomab and recombinant human (rh) Apo2L/TRAIL, were presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO).
